Sugi Predict
/ Targets
/ UBE3C
Top predicted compounds (top 20 by supporting neighbours, then confidence)
| Compound | Confidence | Supporting neighbours |
|---|
Clinical trials — most relevant to UBE3C by text similarity (a relevance ranking, not an exhaustive list)
| Trial | Phase | Status |
|---|
| Phase 3 Efficacy and Safety Study of GTX-102 in Pediatric Subjects With Angelman Syndrome (AS) |
PHASE3 | ACTIVE_NOT_RECRUITING |
| Platform Trial to Compare Homologous Boost of Authorized COVID-19 Vaccines and Heterologous Boost With UB-612 Vaccine |
PHASE3 | UNKNOWN |
| Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent, in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage Mesothelioma |
PHASE2 | SUSPENDED |
| Alrizomadlin (APG-115) in Subjects With BAP1 Cancer Syndrome and Early-Stage Mesothelioma |
PHASE2 | WITHDRAWN |
| Study With Trabectedin in BRCA1 and BRCA2 Mutation Carrier and BRCAness Phenotype Ovarian Cancer |
PHASE2 | UNKNOWN |
| Olaparib in Patients With HRD Malignant Mesothelioma |
PHASE2 | RECRUITING |
| Relapsed and/or Refractory Non-Hodgkin Lymphoma Study |
PHASE2 | WITHDRAWN |
| A Study of UBT251 in Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH) |
PHASE2 | RECRUITING |
| 3K3A-APC for Treatment of Amyotrophic Lateral Sclerosis (ALS) |
PHASE2 | COMPLETED |
| Phase II Study of Vandetanib in Individuals With Kidney Cancer |
PHASE2 | COMPLETED |
| A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7248824 in Participants With Angelman Syndrome (AS) |
PHASE1 | COMPLETED |
| A Extension Study to Evaluate the Safety, Tolerability, and Immunogenicity of UB-612 COVID-19 Vaccine |
PHASE1 | COMPLETED |
| Pharmacokinetic and Tolerability Study of NFC-1 in Subjects Aged 6-17 Years With ADHD |
PHASE1 | COMPLETED |
| Clinical Trial of Levodopa/Carbidopa ( Sinemet) Therapy in Angel Man Syndrome |
nan | COMPLETED |
| Clinical Study of 68Ga-DOTA-BLP PET Imaging in Noninvasive Diagnosis of Malignant Tumors |
nan | NOT_YET_RECRUITING |
| A Natural History Study of Angelman Syndrome |
nan | RECRUITING |
| Biomarkers in Tumor Samples From Younger Patients With Neuroblastoma |
nan | COMPLETED |
| Prognostic Value of Combined Approach Based on KEAP1/NFE2L2 Mutations and Pre-therapeutic FDG-PET/CT Radiomic Analysis in Advanced Non-small-cell Lung Cancer PDL1 ≥ 50% Treated With Pembrolizumab (PEMBROMIC) |
nan | UNKNOWN |
| Long Term Follow-Up of Patients With Mesothelioma and Individuals With Germline Mutations in BAP1 |
nan | RECRUITING |
| Prospective Evaluation of High Resolution Dual Energy Computed Tomographic Imaging, Noninvasive (Liquid) Biopsies, and Minimally Invasive Surgical Surveillance for Early Detection of Mesotheliomas in Patients With BAP1 Tumor Predisposition Syndrome |
nan | RECRUITING |
| Exercise Therapy to Reduce Heart Failure Symptoms; Sorting Mechanisms of Benefit |
nan | COMPLETED |
| CDH1 Germline Mutations in Lobular Breast Cancer |
nan | COMPLETED |
| Characterization of Angelman Syndrome |
nan | COMPLETED |
| Genes Contributing to Hereditary Ovarian Cancer in Women and BRCA1/2 Wildtype Families |
nan | COMPLETED |
| Endocrine Disruptors and Life STILe in Breast Cancer Development |
nan | UNKNOWN |
| Von Hippel-Lindau (VHL): Clinical Manifestations, Diagnosis, Management and Molecular Bases of Inherited Renal and Other Urologic Malignant Disorders |
nan | RECRUITING |
| HRQoL and Financial Toxicity in Patients With VEXAS Syndrome |
nan | RECRUITING |
| Minocycline in the Treatment of Angelman Syndrome |
nan | COMPLETED |
| Autophagy in Systemic Lupus Erythematosus |
nan | UNKNOWN |
| Assessing the Polygenic Burden of Rare Disruptive Mutations in Parkinson's Disease |
nan | UNKNOWN |
Related proteins — ESM-2 sequence neighbours (a UBE3C binder may also engage these)